ES2133270T3 - Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna. - Google Patents

Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.

Info

Publication number
ES2133270T3
ES2133270T3 ES90909598T ES90909598T ES2133270T3 ES 2133270 T3 ES2133270 T3 ES 2133270T3 ES 90909598 T ES90909598 T ES 90909598T ES 90909598 T ES90909598 T ES 90909598T ES 2133270 T3 ES2133270 T3 ES 2133270T3
Authority
ES
Spain
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
prophylaxis
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90909598T
Other languages
English (en)
Inventor
Fernand Labrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endorecherche Inc
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Application granted granted Critical
Publication of ES2133270T3 publication Critical patent/ES2133270T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fertilizers (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA TERAPIA DE COMBINACION PARA LA PROFILAXIS Y/O TRATAMIENTO DE HIPERPLASIA PROSTATICA BENIGNA EN ANIMALES DE SANGRE CALIENTE SUSCEPTIBLES QUE COMPRENDE EL ADMINISTRAR UNA COMBINACION DE DOS O MAS COMPUESTOS SELECCIONADOS DEL GRUPO QUE CONSISTE EN UN INHIBIDOR DE ACTIVIDAD DE REDUCTASA-5(ALFA), UN ANTI-ESTROGENO, UN INHIBIDOR DE ACTIVIDAD AROMATASA, UN INHIBIDOR DE ACTIVIDAD DEHIDROGENASA 17(BETA)-HIDROXIESTEROIDE Y, EN ALGUNOS CASOS, UN ANTI-ANDROGENO Y/O UN AGONISTA LHRH. SE DESCRIBEN TAMBIEN COMPOSICIONES FARMACEUTICAS UTILES PARA TAL TRATAMIENTO Y EQUIPOS FARMACEUTICOS CONTENIENDO TALES COMPOSICIONES.
ES90909598T 1989-07-07 1990-07-05 Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna. Expired - Lifetime ES2133270T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37670089A 1989-07-07 1989-07-07

Publications (1)

Publication Number Publication Date
ES2133270T3 true ES2133270T3 (es) 1999-09-16

Family

ID=23486098

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90909598T Expired - Lifetime ES2133270T3 (es) 1989-07-07 1990-07-05 Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.
ES99106510T Expired - Lifetime ES2222633T3 (es) 1989-07-07 1990-07-05 Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99106510T Expired - Lifetime ES2222633T3 (es) 1989-07-07 1990-07-05 Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna.

Country Status (17)

Country Link
US (1) US5817649A (es)
EP (3) EP0943328B1 (es)
JP (2) JP3332377B2 (es)
KR (1) KR920703063A (es)
AT (2) ATE177949T1 (es)
AU (2) AU643445B2 (es)
CA (1) CA2062973C (es)
DE (2) DE69034148T2 (es)
DK (2) DK0943328T3 (es)
ES (2) ES2133270T3 (es)
HU (1) HU223662B1 (es)
IE (2) IE990530A1 (es)
IL (1) IL94990A (es)
MY (1) MY106484A (es)
NZ (1) NZ234414A (es)
WO (1) WO1991000731A1 (es)
ZA (1) ZA905312B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
CA2062792C (en) * 1989-07-07 2006-03-21 Fernard Labrie Treatment of androgen-related diseases
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
MXPA00008868A (es) 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
DE50016101D1 (de) * 1999-08-13 2011-06-09 Curadis Gmbh Substanzen und mittel zur positiven beeinflussung von kollagen
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
CZ20024214A3 (cs) 2000-06-28 2003-04-16 Bristol-Myers Squibb Company Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití
JP3908162B2 (ja) * 2000-06-30 2007-04-25 中外製薬株式会社 新規な抗アンドロゲン剤
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002259147A1 (en) 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
IL160065A0 (en) 2001-09-06 2004-06-20 Schering Corp 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2463626C (en) 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PL206962B1 (pl) 2001-12-19 2010-10-29 Bristol Myers Squibb Co Związek heterocykliczny o budowie skondensowanej
AU2003290799A1 (en) 2002-11-18 2004-06-15 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60323765D1 (de) 2002-12-17 2008-11-06 Schering Corp Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
BRPI0516243C1 (pt) 2004-10-20 2021-05-25 Endorecherche Inc uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
EP3868323B1 (en) * 2007-01-02 2023-09-06 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US8814921B2 (en) * 2008-03-06 2014-08-26 Aquabeam Llc Tissue ablation and cautery with optical energy carried in fluid stream
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
WO2015035249A2 (en) 2013-09-06 2015-03-12 Procept Biorobotics Corporation Automated image-guided tissue resection and treatment
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
CN104203078B (zh) 2012-02-29 2018-04-20 普罗赛普特生物机器人公司 自动化图像引导的组织切除和处理
ES2681023T3 (es) * 2012-02-29 2018-09-11 Repros Therapeutics Inc. Terapia de combinación para tratar el déficit de andrógenos
JP6403695B2 (ja) 2013-02-14 2018-10-10 プロセプト バイオロボティクス コーポレイション アクアアブレーションアクアビーム眼科手術方法および装置
CN106572864B (zh) 2014-06-30 2020-06-09 普罗赛普特生物机器人公司 流体射流组织切除和寒凝装置
EP3188662B1 (en) 2014-09-05 2024-09-11 PROCEPT BioRobotics Corporation Physician controlled tissue resection integrated with treatment mapping of target organ images

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
US4087461A (en) * 1976-02-26 1978-05-02 The Johns Hopkins University Anti-androgenic steroids
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4347363A (en) * 1981-09-17 1982-08-31 Sterling Drug Inc. Process for preparing 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriles
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
GR79447B (es) * 1982-12-31 1984-10-30 Mortimer Christopher H Dr
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
AU584070B2 (en) * 1983-12-12 1989-05-18 Edwin G. Kaszynski Hair growth modification
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
DE3586053D1 (de) * 1984-08-02 1992-06-17 Labrie Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
EP0177654B1 (fr) * 1984-10-10 1989-05-31 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Association synergique contraceptive
GB8503940D0 (en) * 1985-02-15 1985-03-20 Erba Farmitalia 4-substituted androstendione derivatives
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia

Also Published As

Publication number Publication date
DE69033020D1 (de) 1999-04-29
JP3332377B2 (ja) 2002-10-07
ATE269066T1 (de) 2004-07-15
WO1991000731A1 (en) 1991-01-24
ATE177949T1 (de) 1999-04-15
DK0943328T3 (da) 2004-10-18
EP0857487A3 (en) 1999-12-08
ES2222633T3 (es) 2005-02-01
HUT60138A (en) 1992-08-28
HU223662B1 (hu) 2004-11-29
HU9200047D0 (en) 1992-06-29
AU643445B2 (en) 1993-11-18
US5817649A (en) 1998-10-06
EP0480950B1 (en) 1999-03-24
IL94990A (en) 1997-01-10
AU5217493A (en) 1994-02-10
KR920703063A (ko) 1992-12-17
IE990531A1 (en) 2000-11-15
DK0480950T3 (da) 1999-10-11
DE69033020T2 (de) 1999-08-05
AU5854590A (en) 1991-02-06
EP0943328A3 (en) 1999-12-08
IL94990A0 (en) 1991-06-10
DE69034148T2 (de) 2005-06-30
JPH04506798A (ja) 1992-11-26
ZA905312B (en) 1992-02-26
AU668434B2 (en) 1996-05-02
MY106484A (en) 1995-05-30
EP0480950A1 (en) 1992-04-22
CA2062973C (en) 2003-09-23
DE69034148D1 (de) 2004-07-22
EP0943328A2 (en) 1999-09-22
JP2001354590A (ja) 2001-12-25
CA2062973A1 (en) 1991-01-08
IE990530A1 (en) 2000-11-15
NZ234414A (en) 1999-05-28
IE902459A1 (en) 1991-02-13
EP0943328B1 (en) 2004-06-16
EP0857487A2 (en) 1998-08-12

Similar Documents

Publication Publication Date Title
ES2133270T3 (es) Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
TR199802273T2 (xx) Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ES2055745T3 (es) Compuestos antigestagenicos y antiestrogenos para el tratamiento de tumores hormono-dependientes.
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
SE7903186L (sv) Cerebralverksamt medel
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
PT705100E (pt) Guanidinas substituidas terapeuticas
FI951856A0 (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
BG100930A (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
DE3875866D1 (de) Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie.
SE9604348D0 (sv) Användning av hydroxyguanidiner
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 480950

Country of ref document: ES